Skip Navigation



ToxSci Advance Access published online on February 5, 2007
Toxicological Sciences, doi:10.1093/toxsci/kfm012
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
97/1/32    most recent
kfm012v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Korashy, H. M.
Right arrow Articles by El-Kadi, A. O.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Korashy, H. M.
Right arrow Articles by El-Kadi, A. O.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Induction of Cytochrome P450 1A1 by Ketoconazole and Itraconazole but not Fluconazole, in Murine and Human Hepatoma Cell Lines

INDUCTION OF CYP1A1 BY ANTIFUNGAL DRUGS

Hesham M. Korashy, Anooshirvan Shayeganpour, Dion R. Brocks and Ayman O.S. El-Kadi{dagger}

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada T6G 2N8

{dagger} Corresponding Author: Ayman O.S. El-Kadi, PhD, Faculty of Pharmacy & Pharmaceutical Sciences, 3126 Dentistry / Pharmacy Centre, University of Alberta, Edmonton, Alberta, Canada T6G 2N8, Phone: 780-492-3071; Fax: 780-492-1217, E-mail: aelkadi{at}pharmacy.ualberta.ca

Received December 8, 2006; accepted January 26, 2007


  Abstract

Azole antifungal agents are widely prescribed drugs for the treatment of systemic fungal infections; however, since their introduction into the market, increasing evidences of hepatotoxicity have been reported. Therefore, we examined the ability of three structurally different antifungal drugs, ketoconazole (KTZ), itraconazole (ITZ), and fluconazole (FLZ) to induce the CYP1A1, an enzyme known to play an important role in chemical activation of xenobiotics to toxic metabolites. KTZ and ITZ, but not FLZ, induced the CYP1A1 in murine Hepa 1c1c7 and human HepG2 hepatoma cells at the mRNA, protein and activity levels in a concentration- and time-dependent manner. The increases in Cyp1a1 mRNA levels mediated by KTZ and ITZ were completely blocked by the RNA synthesis inhibitor, actinomycin D, whereas the level of existing mRNA was not altered, implying a requirement of de novo RNA synthesis through a transcriptional mechanism. The ability of these drugs to directly activate the aryl hydrocarbon receptor (AhR) transformation and hence xenobiotic responsive elements (XRE) binding was strongly correlated with their abilities to induce luciferase activity. Inhibition studies showed that KTZ and ITZ, in addition to being CYP1A1 inducers, are substrates and competitive inhibitors. This study provides the first evidence for the ability of KTZ and ITZ to induce the CYP1A1 gene expression through an AhR-dependent mechanism, and suggests a novel mechanism of the KTZ- and ITZ-mediated toxicities.

Key Words: CYP1A1; Aryl hydrocarbon receptor; Antifungal drugs; Carcinogenesis; Hepatotoxicity; Transcription.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.